MyFinsight
Home
Blog
About
Proceeds from the
issuance of common stock,...
$9,685,402
Proceeds from the
issuance of common stock,...
$9,227,761
Maturities of marketable
securities
$5,000,000
(-77.27%↓ Y/Y)
Net cash provided by
financing activities
$18,913,163
(312.17%↑ Y/Y)
Net cash provided by
investing activities
$2,526,088
(-50.87%↓ Y/Y)
Canceled cashflow
$2,473,912
Net (decrease)
increase in cash and cash...
$14,520,826
(2239.24%↑ Y/Y)
Canceled cashflow
$6,918,425
Prepaid expenses and
other assets
-$961,623
(-1730.78%↓ Y/Y)
Stock-based compensation
expense
$362,275
(-57.79%↓ Y/Y)
Purchase of marketable
securities
$2,473,912
(-85.33%↓ Y/Y)
Net cash used in
operating activities
-$6,918,425
(33.53%↑ Y/Y)
Canceled cashflow
$1,323,898
Net loss
-$6,571,656
(41.07%↑ Y/Y)
Accounts payable
-$1,532,371
(-662.15%↓ Y/Y)
Accrued expenses and
other current...
-$119,157
(-127.83%↓ Y/Y)
Accretion of discount on
marketable securities, net
$19,139
(-96.07%↓ Y/Y)
Back
Back
Cash Flow
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)
source: myfinsight.com